Results 201 to 210 of about 276,970 (298)

Prognostic Impact of Pre-Treatment CRP/Albumin Ratio in Patients with Advanced-Stage Epithelial Ovarian Cancer. [PDF]

Onco Targets Ther
Atalah F, Karakök A, Acarbay A, Beşiroğlu M, Gümüş M.   +4 more
europepmc   +1 more source

HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma

International Journal of Cancer, EarlyView.
What's New? Ovarian clear cell carcinoma is highly associated with hypoxia. Hypoxia‐inducible factor 2A (HIF2A) is a key regulator of hypoxic responses, but its role in ovarian clear cell carcinoma remains unclear. This study demonstrated the unfavorable prognostic significance of HIF2A expression in ovarian clear cell carcinoma.
Mengxin Jiang, Ken Yamaguchi, Kohei Hamada, Yuko Hosoe, Yuka Mise, Sachiko Kitamura, Zhihong Liu, Hairong Wei, Zhenhai Gao, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Rin Mizuno, Taito Miyamoto, Junzo Hamanishi, Masaki Mandai   +15 more
wiley   +1 more source

Multigene germline and somatic testing for epithelial ovarian cancer in China. [PDF]

NPJ Precis Oncol
Li L, Zhang J, Song N, Sun B, Zhang D, Li Y, Gao Y, Wu K, Li Q, Lin C, Cui H, Cao B, Wang L, Shao K, You Y, Wu H, Lang J, Wu M.   +17 more
europepmc   +1 more source

Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment

, 2020
Berger, H., Braicu, E., Chekerov, R., Darb-Esfahani, S., Hoffmann, K., Kessler, M., Kulbe, H., Mangler, M., Meyer, T., Mollenkopf, H., Sehouli, J., Taube, E., Thillainadarasan, S., Zemojtel, T.   +13 more
core   +1 more source

The cervico‐vaginal DNA methylation WID‐qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer

International Journal of Cancer, EarlyView.
What's New? The DNA methylation‐based WID‐qEC test has been validated for the accurate detection of endometrial and cervical cancers using cervico‐vaginal samples. However, a small proportion of women test positive despite the absence of these cancers. This study explored the associated biological and clinical characteristics to inform potential follow‐
Elisa Redl, Chiara Herzog, Charlotte Vavourakis, James Barrett, Allison Jones, Iona Evans, Daniel Reisel, Ranjit Manchanda, Line Bjørge, Michal Zikan, David Cibula, Twana Alkasalias, Angelique Flöter Rådestad, Kristina Gemzell‐Danielsson, Louis Dubeau, Nicola MacDonald, Davor Jurkovic, Nora Pashayan, Martin Widschwendter   +18 more
wiley   +1 more source

Clinical significance of differential plasma proteins levels in the diagnosis of epithelial ovarian cancer. [PDF]

World J Exp Med
Ibrahim NH, Abdellateif MS, Serag DS, Laymouna A, Elaguizy MS, Halim RMA.   +5 more
europepmc   +1 more source

Combination of transvaginal ultrasound with cervical cancer screening contributes to early detection of ovarian cancer: Clinical trial

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective Early detection of ovarian cancer at stage I is important to improve patients‘ prognosis. The goal of this study was to examine if transvaginal ultrasound (TVU) performed at the same time as cervical cancer screening can facilitate early detection of ovarian cancer.
Hiromasa Fujita, Kazuhira Okamoto, Hidenori Kato, Hidemichi Watari, Nobuyoshi Ozawa, Mitsuaki Suzuki   +5 more
wiley   +1 more source

Prognostic Impact of Postoperative Systemic Immune-Inflammation Index Changes in Epithelial Ovarian Cancer. [PDF]

Cancers (Basel)
Chung YE, Paik ES, Kim M, Kim NH, Lim S, Seo JH, Choi CH, Kim TJ, Lee JW, Lee YY.   +9 more
europepmc   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination. [PDF]

Commun Biol
Gruet M, Xu Y, An L, Ma Y, Balcells C, Tyson K, Evangelista LC, Spear S, Xu Y, McKinney F, Babuta J, Bray C, Wickremesinghe C, Siskos AP, Nijhuis AM, Tate EW, McNeish IA, Benito A, Keun HC.   +18 more
europepmc   +1 more source